Moleculin Biotech Inc. announced it has received a Notice of Intent to Grant for its European patent application titled "PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE." This development is expected to solidify the company's exclusivity of Annamycin, also known as naxtarubicin, in the European Union. The patent, once granted, will cover methods of making preliposomal Annamycin lyophilizate with improved stability and high purity, with a base patent term extending until 2040. This advancement is part of Moleculin's efforts to establish Annamycin as the first non-cardiotoxic anthracycline for the treatment of acute myeloid leukemia and soft tissue sarcoma lung metastases.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-023863), on July 30, 2025, and is solely responsible for the information contained therein.